Company Overview
M. K. Proteins Limited manufactures and trades vegetable refined oil and by-products in India. It offers rice bran, sunflower, cotton seed, soya bean, palm, canola, and rice bran bleached oils. The company also provides by-products, including rice bran fatty acid oils, rice bran waxes, gums, and spent earth; imports, processes, and sells crude oils; as well as trades in edible and non-edible oils. M. K. Proteins Limited was incorporated in 2012 and is based in Ambala, India.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Mar 2026 Revenue of ₹382.88 Cr (+43.0% YoY); net profit ₹6.83 Cr.
- Trailing 12 Months Year-on-year growth — revenue +0.2%, earnings -55.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 6.7%, profit CAGR -14.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 6.74% |
| 1 Year: | 0.20% |
Compounded Profit Growth
| 5 Years: | -14.52% |
| 1 Year: | -55.60% |
Stock Price Performance
| 1 Year: | -42.84% |
| 6 Months: | -26.15% |
| 3 Months: | -9.37% |
| 1 Month: | -2.52% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)39.94 · Neutral
P/E of 29.77 is above the sector median of 20.10 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Earnings shrank at -14.5% CAGR over 5 years.
- Trading 49.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Consumer Defensive).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MKPL M. K. Proteins Limited NSE | 3.87 | 29.77 | ₹145.27 Cr | 0.00% | 14.29% | 8.95% | 6.74% | -14.52% |
| 2 | HINDUNILVR Hindustan Unilever Limited NIFTY50NSE | 1,850.20 | 41.21 | ₹4.35 L Cr | 2.36% | 22.15% | 30.86% | 2.31% | 14.12% |
| 3 | ITC ITC Limited NIFTY50NSE | 262.00 | 15.86 | ₹3.28 L Cr | 6.27% | 36.47% | 28.53% | 3.65% | 2.54% |
| 4 | NESTLEIND Nestlé India Limited NIFTY50NSE | 1,223.90 | 61.91 | ₹2.36 L Cr | 0.91% | 62.44% | 79.99% | 17.01% | 23.05% |
| 5 | DMART Avenue Supermarts Limited NSE | 3,250.90 | 69.30 | ₹2.12 L Cr | 0.00% | 16.41% | 12.14% | 17.14% | 7.69% |
| 6 | VBL Varun Beverages Limited NSE | 408.40 | 40.84 | ₹1.38 L Cr | 0.46% | 19.44% | 16.85% | 17.26% | 26.57% |
| 7 | BRITANNIA Britannia Industries Limited NSE | 4,683.60 | 43.32 | ₹1.13 L Cr | 1.89% | 61.21% | 49.61% | 5.66% | 2.95% |
| 8 | MARICO Marico Limited NIFTY_MIDNSE | 775.65 | 53.27 | ₹1.01 L Cr | 0.51% | 38.75% | 41.85% | 11.82% | 10.61% |
| 9 | TATACONSUM Tata Consumer Products Limited NIFTY50NSE | 970.65 | 58.76 | ₹96,064.26 Cr | 1.05% | 8.29% | 7.08% | 13.87% | 8.61% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 137.20 Cr | 114.95 Cr | 32.43 Cr | 89.56 Cr | 145.94 Cr |
| Cost of Revenue | - | 131.72 Cr | 106.06 Cr | 30.85 Cr | 86.35 Cr | 142.33 Cr |
| Gross Profit | - | 5.48 Cr | 8.89 Cr | 1.58 Cr | 3.21 Cr | 3.61 Cr |
| Operating Expenses | - | 91.34 L | 3.48 Cr | 64.08 L | 96.52 L | 1.22 Cr |
| Operating Income | - | 4.57 Cr | 5.41 Cr | 94.00 L | 2.24 Cr | 2.39 Cr |
| EBITDA | - | 4.68 Cr | 5.51 Cr | 1.17 Cr | 2.38 Cr | 2.62 Cr |
| Interest Expense | - | 67.44 L | 70.16 L | 6.45 L | 29.56 L | 79.03 L |
| Pretax Income | - | 3.92 Cr | 4.71 Cr | 99.98 L | 1.97 Cr | 1.72 Cr |
| Tax Provision | - | 1.12 Cr | 1.19 Cr | 25.31 L | 53.55 L | 57.91 L |
| Net Income | - | 2.80 Cr | 3.51 Cr | 74.67 L | 1.43 Cr | 1.14 Cr |
| Diluted EPS | - | 0.07 | 0.09 | 0.02 | 0.04 | 0.03 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 314.86 Cr | 245.57 Cr | 267.71 Cr | 382.88 Cr |
| Cost of Revenue | - | 294.37 Cr | 223.92 Cr | 252.53 Cr | 368.43 Cr |
| Gross Profit | - | 20.49 Cr | 21.65 Cr | 15.18 Cr | 14.45 Cr |
| Operating Expenses | - | 3.69 Cr | 5.19 Cr | 3.10 Cr | 3.46 Cr |
| Operating Income | - | 16.81 Cr | 16.46 Cr | 12.08 Cr | 10.98 Cr |
| EBITDA | - | 17.65 Cr | 17.06 Cr | 12.91 Cr | 11.68 Cr |
| Interest Expense | - | 1.84 Cr | 1.07 Cr | 1.10 Cr | 1.85 Cr |
| Pretax Income | - | 14.99 Cr | 15.47 Cr | 11.45 Cr | 9.39 Cr |
| Tax Provision | - | 4.06 Cr | 4.26 Cr | 3.05 Cr | 2.56 Cr |
| Net Income | - | 10.93 Cr | 11.21 Cr | 8.40 Cr | 6.83 Cr |
| Diluted EPS | - | 0.29 | 0.30 | 0.22 | 0.18 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 103.22 Cr | 96.25 Cr | 130.57 Cr | 131.20 Cr |
| Current Assets | - | 98.58 Cr | 85.83 Cr | 118.52 Cr | 118.23 Cr |
| Cash & Equivalents | - | 6.25 L | 9.23 L | 3.38 L | 43.82 L |
| Inventory | - | 71.20 Cr | 79.27 Cr | 111.32 Cr | 109.78 Cr |
| Receivables | - | 16.06 Cr | 3.57 Cr | 1.40 Cr | 2.11 Cr |
| Total Liabilities | - | 53.36 Cr | 35.17 Cr | 61.10 Cr | 54.90 Cr |
| Current Liabilities | - | 49.63 Cr | 33.96 Cr | 59.00 Cr | 52.54 Cr |
| Long Term Debt | - | 2.54 Cr | 0 | 83.04 L | 1.05 Cr |
| Total Debt | - | 45.53 Cr | 20.08 Cr | 38.72 Cr | 37.14 Cr |
| Total Equity | - | 49.86 Cr | 61.08 Cr | 69.47 Cr | 76.30 Cr |
| Shares Outstanding | - | 37.54 Cr | 37.54 Cr | 37.54 Cr | 37.54 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -5.87 Cr | 32.42 Cr | -16.13 Cr | 5.43 Cr |
| Investing Cash Flow | - | 1.34 L | -5.88 Cr | -1.48 Cr | -1.60 Cr |
| Financing Cash Flow | - | 5.92 Cr | -26.51 Cr | 17.55 Cr | -3.43 Cr |
| Capital Expenditure | - | -72,052 | -5.90 Cr | -2.22 Cr | -1.90 Cr |
| Free Cash Flow | - | -5.88 Cr | 26.51 Cr | -18.35 Cr | 3.54 Cr |
| Net Change in Cash | - | 5.58 L | 2.98 L | -5.85 L | 40.44 L |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 6.5% | 8.8% | 5.7% | 3.8% |
| Operating Margin % | - | 5.3% | 6.7% | 4.5% | 2.9% |
| Net Margin % | - | 3.5% | 4.6% | 3.1% | 1.8% |
| ROE % | - | 21.9% | 18.4% | 12.1% | 9.0% |
| ROCE % | - | 31.4% | 26.4% | 16.9% | 14.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MKPL
Proteins (MKPL.NS) Adds +0.51% to Recent Winning Streak 2026-10-19 - Debt Free Companies - www.siam.in
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPNVdaTE9senFBMUdSNElaOHJHN0prNk1iYVpYMGViVXRta3NkLTk4bUFzWFdmdHktd2E0SzA5c05CcUZIdVZEOUNvQ1F0LS1ZeGc3bDdsWkI1UUpkbm9heFZVUnVEb3c4cTRiZGVZQ3p4TzRTQVRCdkYtOF93T2IwYnJFX2VOMDh5WGhoTl…
MKPL Stock Prediction 2026: Analyst Forecast and Analysis - Univest
<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE9ZZzF2Mm1Qd1FIb2tfWVQwTktkbWhoRDFMSzhjRldGTVdSWjJHTXhnVDhWclFycU5EUzc2WlF1MEFady01a1J2SHdqTlRVZDVwZzUtZFYxUU1VVFNuemRVWg?oc=5" target="_blank">MKPL Stock Prediction 2026: Analyst F…
Unpleasant Surprises Could Be In Store For M. K. Proteins Limited's (NSE:MKPL) Shares - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxNalhHbUQ1bjZ1VlEzSHlsWTlDaUREYkx0amhEcXhrUFFpNzRLc05DMGhUdEdjUHB5dzJqMXg4SWNmUkd6ZklCX3FWdG9wVEZER01jckhxQnMxVHJzVlpFVHF3Z21ZcngzSEVyc0NaNW9iS3VBUGNFOWw2UjVZRjBSMVVLSUdlVG5DN1B5eU…
M. K. Proteins Limited (MKPL.NS) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTFByWllxRjZjaTFYSTAyZlZuQi00eEFmVEFhOHo0UTJING5JNF82elNWd0twNllwZDAxQWM1TzFaQkM3N1pFbm5ZM1A1aHl1Wm1RdjI4SU9R?oc=5" target="_blank">M. K. Proteins Limited (MKPL.NS) Stock Price, News,…
M K Proteins (MKPL.NS) Slips 1.24% to ₹3.98 as Stock Tests Lower Half of ₹3.78–₹4.18 Range - Death Cross - siam.in
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxONTdzZVhmcl8tZnpRanJ5TDJnNnlMS1VVMXRpcjZIRWdhb2JVckxFYm12bnAxUmNQMFZYMFl1dENiMG1pNEEzMXVKMnRmaEw2VTFuNjlvaU5oTzJ5YVVKTG1MenhRLWNib3VBVWZ0VmxGbUdHU3lHM0ZoOXlBNl9ldkVwdTNua21xelpYWT…
Why Is MK Proteins Share Price Falling Key Reasons 2026 - Univest
<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTE9rd0JJVnVZcFVMZWlKOHM0Q0lTWGszU3NLUGduSmlRY3ZYaXc2MXFLRkxfZ3pmVnNOODBUN3JDdnNkX0h2QlduRWsydUt2T3cxTUxVYnFXYlpIeU9ILVlQdDRmLTJ5T2VvQzh5MnlvcHc?oc=5" target="_blank">Why Is MK Protei…
MKPL — Frequently Asked Questions
What is the current share price of M. K. Proteins Limited (MKPL)?
As of 2026-10-23 04:58 IST, M. K. Proteins Limited (MKPL) trades at ₹3.87 on NSE. Its 52-week range is ₹3.87 to ₹7.61.
What is the market capitalisation of MKPL?
M. K. Proteins Limited (MKPL) has a market capitalisation of ₹145.27 Cr on NSE.
What is the P/E ratio of MKPL?
MKPL trades at a trailing price-to-earnings (P/E) ratio of 29.77. The industry average P/E is 20.10. Its price-to-book (P/B) ratio is 1.97.
What is the return on equity (ROE) of MKPL?
MKPL has a return on equity (ROE) of 8.95%. Its return on capital employed (ROCE) is 14.29%.
Is MKPL a good stock to buy?
This page provides a data-driven analysis of M. K. Proteins Limited (MKPL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.